EXOZ
EXOZYMES INC.
NASDAQ · Healthcare · Biotechnology · US
$4.00
−5.33%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -42.2%
- EBIT
- -30.5%
- EPS
- -4.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- -60.5%
- EBIT
- -63.8%
- Net income
- -56.3%
- EPS
- -51.4%
- Free cash flow
- +25.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026